Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

Each RSU vests over three years with 33 1/3% vesting on each anniversary, conditioned on continued service through each vesting date.

Key Figures

Inducement RSUs granted: 1,799 RSUs Number of new employees: 4 employees Vesting period: 3 years +5 more

8 metrics

Inducement RSUs granted 1,799 RSUs Aggregate awards to four new hires as of Jan 31, 2026

Number of new employees 4 employees Recipients of inducement RSU grants

Vesting period 3 years RSUs vest over three consecutive anniversaries of Grant Date

Annual vesting rate 33 1/3% Portion of RSU grant vesting on each anniversary

Grant Date January 31, 2026 Effective date for the RSU inducement awards

Resale registration shares 2,805,688 shares Common stock registered for resale under S-3 dated Nov 3, 2025

Beneficial ownership stake 8.6% Affinity Asset Advisors and Michael Cho as of Jan 22, 2026

Shares outstanding reference 19,883,800 shares Shares used to calculate 13G/A ownership percentages

Market Reality Check

Price: $6.31 Vol: Volume 267,697 is below t...

low vol

$6.31 Last Close

Volume Volume 267,697 is below the 20-day average of 428,084, suggesting limited pre-news trading interest. low

Technical Shares at $6.52 trade above the $5.71 200-day MA but remain 37.73% below the $10.47 52-week high.

Peers on Argus

KPTI was down 1.66% while close biotech peers showed mixed moves (e.g., CUE -4.7...

KPTI was down 1.66% while close biotech peers showed mixed moves (e.g., CUE -4.75%, PYPD -2.97%, APLT +8.67%, MAIA +5.7%), indicating stock-specific rather than sector-driven trading.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim. 2025 results	Positive	-5.6%	Preliminary 2025 revenue outlook and 2026 Phase 3 data timing.
Jan 02	Inducement RSU grants	Neutral	+2.9%	RSU inducement awards to two new hires under 2022 plan.
Dec 08	Conference participation	Neutral	+2.4%	Virtual fireside chat in Baird’s Biotech Discovery Series.
Dec 01	Options and RSU grants	Neutral	-6.8%	Stock options and RSUs as inducement awards for new hires.
Dec 01	Conference appearance	Neutral	+2.3%	Participation in Piper Sandler healthcare conference fireside chat.

Pattern Detected

Recent KPTI news has produced mixed reactions, with one positive fundamental update drawing a negative move while routine conference and inducement items have seen modest positive or limited reactions.

Recent Company History

Over the past few months, Karyopharm has balanced financing, clinical, and corporate updates. On Jan 12, 2026, it outlined preliminary 2025 revenue of about $145M and multiple Phase 3 readouts for 2026, yet the stock fell. Prior items included repeated inducement equity grants under the 2022 Inducement Stock Incentive Plan and participation in investor conferences. Compared with today’s small RSU grants to four new hires, the historical items were more strategic or financial in nature, but market reactions have not followed a consistent pattern.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration dated Nov 3, 2025 covers up to 2,805,688 shares of common stock for selling stockholders. The company is not selling securities under this registration and would only receive cash upon any warrant exercises.

Market Pulse Summary

This announcement details a routine equity compensation action: 1,799 RSUs granted to four new hires...

Analysis

This announcement details a routine equity compensation action: 1,799 RSUs granted to four new hires under the 2022 Inducement Stock Incentive Plan, vesting over three years at 33 1/3% annually. Prior months featured similar inducement grants plus more material updates on revenue outlook, financing and resale registrations. Investors evaluating this news alongside earlier filings may focus more on liquidity, debt obligations and upcoming clinical and revenue milestones than on today’s modest dilution from employee awards.

Key Terms

restricted stock units (rsus), nasdaq listing rule 5635(c)(4), inducement stock incentive plan

3 terms

restricted stock units (rsus) financial

"granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. Not financial advice.

NEWTON, Mass., Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of January 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in more than 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302673225.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What did Karyopharm (KPTI) announce about inducement RSU grants on February 2, 2026?

Karyopharm granted 1,799 RSUs to four new hires effective January 31, 2026. According to the company, the awards were made under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

How do the 1,799 RSUs granted by KPTI vest and when do they begin vesting?

The RSUs vest over three years with 33 1/3% vesting on each anniversary. According to the company, the Grant Date was January 31, 2026, and vesting depends on continued service through each anniversary.

Who received the RSU awards from Karyopharm (KPTI) and under what plan were they granted?

Four newly hired employees received the RSU awards as inducements to join the company. According to the company, grants were made under the 2022 Inducement Stock Incentive Plan, as amended, pursuant to Nasdaq rule 5635(c)(4).

Do Karyopharm's (KPTI) RSU awards include performance conditions or only service-based vesting?

The RSU awards are service-based and vest based on continued employment or service through each vesting date. According to the company, vesting is explicitly conditioned on continued service, not on additional performance metrics.

What is the significance of Nasdaq Listing Rule 5635(c)(4) for KPTI's RSU grants?

Rule 5635(c)(4) permits equity inducements for new hires outside prior shareholder-approved plans. According to the company, the RSU awards were granted specifically as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).